Literature DB >> 27043544

The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges.

Rolf Teschke1, Axel Eickhoff2.   

Abstract

In 2013, physicians at the Honolulu Queen's Medical Center (QMC) noticed that seven liver disease patients reported the use of OxyELITE Pro (OEP), a widely consumed dietary supplement (DS). Assuming a temporal association between OEP use and disease, they argued that OEP was the cause of this mysterious cluster. Subsequent reexamination, however, has revealed that this QMC cohort is heterogeneous and not a cluster with a single agent causing a single disease. It is heterogeneous because patients used multiple DS's and drugs and because patients appeared to have suffered from multiple liver diseases: liver cirrhosis, liver failure by acetaminophen, hepatotoxicity by non-steroidal antiinflammatory drugs (NSAIDs), resolving acute viral hepatitis by hepatitis B virus (HBV), herpes simplex virus (HSV), and varicella zoster virus (VZV), and suspected hepatitis E virus (HEV). Failing to exclude these confounders and to consider more viable diagnoses, the QMC physicians may have missed specific treatment options in some of their patients. The QMC physicians unjustifiably upgraded their Roussel Uclaf Causality Assessment Method (RUCAM) causality scores so that all patients would appear to be "probable" for OEP. However, subsequent RUCAM reassessments by our group demonstrated a lack of causality for OEP in the evaluated QMC cases. The QMC's questionable approaches explain the extraordinary accumulation of suspected OEP cases at the QMC in Hawaii as single place, whereas similar cohorts were not published by any larger US liver center, substantiating that the problem is with the QMC. In this review article, we present and discuss new case data and critically evaluate upcoming developments of problematic regulatory assessments by the US Centers for Disease Control and Prevention (CDC), the Hawaii Department of Health (HDOH), and the Food and Drug Administration (FDA), as based on invalid QMC conclusions, clarifying now also basic facts and facilitating constructive discussions.

Entities:  

Keywords:  Centers for Disease Control and Prevention; Food and Drug Administration; Hawaii Department of Health; Honolulu Queen’s Medical Center; OxyELITE Pro; acetaminophen

Mesh:

Year:  2016        PMID: 27043544      PMCID: PMC4848932          DOI: 10.3390/ijms17040476

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  98 in total

Review 1.  Leptospirosis: a zoonotic disease of global importance.

Authors:  Ajay R Bharti; Jarlath E Nally; Jessica N Ricaldi; Michael A Matthias; Monica M Diaz; Michael A Lovett; Paul N Levett; Robert H Gilman; Michael R Willig; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Lancet Infect Dis       Date:  2003-12       Impact factor: 25.071

2.  Development and application of solvent-free extraction for the detection of aflatoxin M1 in dairy products by enzyme immunoassay.

Authors:  Laura Anfossi; Marianna Calderara; Claudio Baggiani; Cristina Giovannoli; Enrico Arletti; Gianfranco Giraudi
Journal:  J Agric Food Chem       Date:  2008-02-15       Impact factor: 5.279

3.  Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  Regul Toxicol Pharmacol       Date:  2012-02-21       Impact factor: 3.271

Review 4.  Green tea extract and the risk of drug-induced liver injury.

Authors:  Rolf Teschke; Li Zhang; Lena Melzer; Johannes Schulze; Axel Eickhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-10-15       Impact factor: 4.481

5.  Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption.

Authors:  R Teschke; G Stutz; G Strohmeyer
Journal:  Biochem Biophys Res Commun       Date:  1979-11-14       Impact factor: 3.575

6.  Acute hepatitis E of a man who consumed wild boar meat prior to the onset of illness in Nagasaki, Japan.

Authors:  Jun-Ichi Masuda; Koji Yano; Yoko Tamada; Yasushi Takii; Masahiro Ito; Katsuhisa Omagari; Shigeru Kohno
Journal:  Hepatol Res       Date:  2005-03-23       Impact factor: 4.288

7.  Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury.

Authors:  Timothy J Davern; Naga Chalasani; Robert J Fontana; Paul H Hayashi; Petr Protiva; David E Kleiner; Ronald E Engle; Hanh Nguyen; Suzanne U Emerson; Robert H Purcell; Hans L Tillmann; Jiezhun Gu; Jose Serrano; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2011-08-16       Impact factor: 22.682

8.  The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.

Authors:  Karl C Klontz; Heidi J DeBeck; Pamela LeBlanc; Kathryn M Mogen; Beverly J Wolpert; Jonathan L Sabo; Monique Salter; Sharon L Seelman; Susan E Lance; Caitlin Monahan; David S Steigman; Kathleen Gensheimer
Journal:  Public Health Rep       Date:  2015 Sep-Oct       Impact factor: 2.792

9.  Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment.

Authors:  Rolf Teschke; Alexander Schwarzenboeck
Journal:  Phytomedicine       Date:  2008-11-17       Impact factor: 5.340

Review 10.  Fatal varicella-zoster hepatitis presenting with severe abdominal pain: a case report and review of the literature.

Authors:  Aline Charabaty Pishvaian; Michelle Bahrain; James H Lewis
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.487

View more
  13 in total

1.  Suspected Liver Injury and the Dilemma of Causality.

Authors:  Rolf Teschke; Axel Eickhoff
Journal:  Dig Dis Sci       Date:  2017-02-16       Impact factor: 3.199

Review 2.  Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?

Authors:  Gaby Danan; Rolf Teschke
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

Review 3.  Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs.

Authors:  Rolf Teschke; Dominique Larrey; Dieter Melchart; Gaby Danan
Journal:  Medicines (Basel)       Date:  2016-07-19

Review 4.  Adverse Effects of Nutraceuticals and Dietary Supplements.

Authors:  Martin J J Ronis; Kim B Pedersen; James Watt
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

Review 5.  Drug induced liver injury with analysis of alternative causes as confounding variables.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Br J Clin Pharmacol       Date:  2018-05-14       Impact factor: 4.335

6.  Herbal Traditional Chinese Medicine and suspected liver injury: A prospective study.

Authors:  Dieter Melchart; Stefan Hager; Sabine Albrecht; Jingzhang Dai; Wolfgang Weidenhammer; Rolf Teschke
Journal:  World J Hepatol       Date:  2017-10-18

7.  Drug, Herb, and Dietary Supplement Hepatotoxicity.

Authors:  Rolf Teschke; Raúl J Andrade
Journal:  Int J Mol Sci       Date:  2016-09-06       Impact factor: 5.923

Review 8.  Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury.

Authors:  Jing Jing; Rolf Teschke
Journal:  J Clin Transl Hepatol       Date:  2017-10-27

Review 9.  Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation.

Authors:  Christian Frenzel; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

Review 10.  Viewpoint: A Contributory Role of Shell Ginger (Alpinia zerumbet (Pers.) B.L. Burtt & R.M. Sm) for Human Longevity in Okinawa, Japan?

Authors:  Rolf Teschke; Tran Dang Xuan
Journal:  Nutrients       Date:  2018-01-31       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.